CompletedNCT00528697
A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
Researchers compared ABT-089, atomoxetine and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.
Medication studyAges 6–12United States
Understand this study
What did researchers investigate?
Researchers compared ABT-089, atomoxetine and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateSeptember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 278
- Sponsor
- AbbVie (prior sponsor, Abbott)
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00528697
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD)
Recruitment & locations
CompletedLittle Rock · El Centro · Boulder
17 more locations
- Bradenton
- Jacksonville
- Orlando
- Northbrook
- Overland Park
- Omaha
- Las Vegas
- Clementon
- Eugene
- Portland
- Salem
- Charleston
- Memphis
- Austin
- Herndon
- Bellevue
- Middleton
Questions about this study
What did researchers investigate?
Researchers compared ABT-089, atomoxetine and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.
Who is behind this study?
The study sponsor is AbbVie (prior sponsor, Abbott).
Did this study involve medication?
Yes. The study involved medication, including ABT-089, atomoxetine and placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)